David Molina

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Ramón De Las Peñas1
Julián Pérez-Beteta1
1Ramón De Las Peñas
1Julián Pérez-Beteta
Learn More
BACKGROUND Antiangiogenic therapies for glioblastoma (GBM) such as bevacizumab (BVZ), have been unable to extend survival in large patient cohorts. However, a subset of patients having angiogenesis-dependent tumors might benefit from these therapies. Currently, there are no biomarkers allowing to discriminate responders from non-responders before the start(More)
  • 1